STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACRV
  4. [Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity

Acrivon insiders report RSU tax withholding, 2.05M shares held

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. insiders report routine share withholding for taxes. President and CEO Dr. Peter Blume-Jensen reported that on 11/21/2025, 19,904 shares of common stock were disposed of at $2.30 per share, identified as shares withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units. Following this transaction, he beneficially owned 2,046,771 shares directly and 314,706 shares indirectly.

The indirect holdings reflect spousal ownership between co-founders Dr. Blume-Jensen and EVP – Business Operations Dr. Kristina Masson. Each spouse disclaims beneficial ownership of the other's securities except to the extent of their pecuniary interest, which clarifies how their combined economic exposure to Acrivon’s stock is reported.

Positive

  • None.

Negative

  • None.
Insider Blume-Jensen Peter, Masson Kristina
Role President and CEO | EVP - Business Operations
Type Security Shares Price Value
Tax Withholding Common Stock 19,904 $2.30 $46K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 2,046,771 shares (Direct); Common Stock — 314,706 shares (Indirect, See Footnote)
Footnotes (1)
  1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Blume-Jensen Peter
(Last) (First) (Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100
(Street)
WATERTOWN MA 02472
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/21/2025 F(1) 19,904 D $2.3 2,046,771 D(2)
Common Stock 314,706 I See Footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Blume-Jensen Peter
(Last) (First) (Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100
(Street)
WATERTOWN MA 02472
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
1. Name and Address of Reporting Person*
Masson Kristina
(Last) (First) (Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100
(Street)
WATERTOWN MA 02472
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director 10% Owner
X Officer (give title below) Other (specify below)
EVP - Business Operations
Explanation of Responses:
1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen 11/25/2025
/s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson 11/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report on this Form 4?

The filing reports that on 11/21/2025, 19,904 shares of Acrivon Therapeutics common stock were disposed of at $2.30 per share, representing shares withheld to cover mandatory tax withholding on vested restricted stock units.

How many Acrivon Therapeutics (ACRV) shares does the CEO own after this transaction?

After the reported transaction, President and CEO Dr. Peter Blume-Jensen beneficially owned 2,046,771 shares of Acrivon Therapeutics common stock directly and 314,706 shares indirectly.

Why were 19,904 Acrivon (ACRV) shares disposed of in this Form 4?

The 19,904 shares were withheld by Acrivon Therapeutics to satisfy the mandatory tax withholding requirement that arises when restricted stock units vest, rather than being sold on the open market by the insider.

Who are the reporting persons in this Acrivon Therapeutics (ACRV) Form 4?

The reporting persons are Dr. Peter Blume-Jensen, President, CEO and Director, and Dr. Kristina Masson, co-founder and EVP – Business Operations, who file jointly because of their spousal relationship and related indirect holdings.

How are spousal ACRV share holdings treated in this Form 4 filing?

The filing notes that shares held by each spouse are reported as indirect holdings for the other, but each of Dr. Blume-Jensen and Dr. Masson disclaims beneficial ownership of the other’s securities except to the extent of their pecuniary interest.

Does this ACRV Form 4 involve derivative securities like options or warrants?

The Form 4 includes a standard Table II heading for derivative securities, but the provided content does not show any specific derivative transactions reported for this date.